Order Article Reprints

Nepal G, Khurana M, Bucheli DH, Bhandari S, Joshi U, Bhagat R, Rehrig JH, Pudasainee P, Shing YK, Ortiz JF, et al. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. Neurology International. 2022; 14(1):99-108. https://doi.org/10.3390/neurolint14010009

Nepal, Gaurav, Mahika Khurana, Domenica Herrera Bucheli, Siddhartha Bhandari, Utsav Joshi, Riwaj Bhagat, Jessica Holly Rehrig, Prasun Pudasainee, Yow Ka Shing, Juan Fernando Ortiz, and et al. 2022. "Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review" Neurology International 14, no. 1: 99-108. https://doi.org/10.3390/neurolint14010009

Nepal, G., Khurana, M., Bucheli, D. H., Bhandari, S., Joshi, U., Bhagat, R., Rehrig, J. H., Pudasainee, P., Shing, Y. K., Ortiz, J. F., Ojha, R., Gajurel, B. P., Quinonez, J., Ruxmohan, S., Albert, T., Licata, S., & Stien, J. (2022). Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. Neurology International, 14(1), 99-108. https://doi.org/10.3390/neurolint14010009